Discover
KALA
KALA BIO, Inc.
1.78
2 x 1.32
2 x 2.09
bid
ask
+
0.05
2.89%
2 @ 04:00 AM
1.84 +0.06 (3.37%)
| Ytd | -93.60% | |
| 1y | -99.26% |
1.62
day range
1.85
1.62
52 week range
1030.00
| Open | 1.71 | Prev Close | 1.73 | Low | 1.62 | High | 1.85 | Mkt Cap | 33.09M |
| Vol | 223.93K | Avg Vol | 107.41K | EPS | -102.01 | P/E | N/A | Forward P/E | -0.90 |
| Beta | -2.14 | Short Ratio | 1.91 | Inst. Own | 48.13% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-08 | 50-d Avg | 3.58 | 200-d Avg | 69.20 | 1yr Est | 15.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-12 | 2024-09 | -2.43 | -1.93 | 0.5 | 20.58% |
| 2024-08-06 | 2024-06 | -4.41 | -3.16 | 1.25 | 28.34% |
| 2024-05-14 | 2024-03 | -2.89 | -4.2 | -1.31 | -45.33% |
| 2024-03-29 | 2023-12 | -3.62 | -3.18 | 0.44 | 12.15% |
| 2023-11-13 | 2023-09 | -2.15 | -3.41 | -1.26 | -58.60% |
| 2023-08-04 | 2023-06 | -3.19 | -4.36 | -1.17 | -36.68% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-15 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-08-19 | Oppenheimer | Upgrade | Outperform | Outperform |
| 2024-05-17 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-04-02 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-04-01 | Oppenheimer | Upgrade | Outperform | Outperform |
| 2023-11-17 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-06-25 | BAZEMORE TODD M | President | 22.39K | Sale |
| 2024-06-10 | BLUMENKRANZ MARK S | Director | 182.82K | Stock Award(Grant) |
| 2024-06-25 | BRAZZELL ROMULUS KIM | Officer | 83.98K | Sale |
| 2024-06-25 | IWICKI MARK T. | Chief Executive Officer | 263.76K | Sale |
| 2024-06-25 | KHARABI DARIUS | Officer | 59.73K | Sale |
| 2024-06-10 | KOVEN ANDREW IAN | Director | 13.92K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Baker Bros. Advisors, LP | 891.34K | 5.35M | 19.33% |
| 2024-09-29 | SR One Capital Management, LP | 443.66K | 2.66M | 9.62% |
| 2024-09-29 | Adar1 Capital Management, LLC | 306.07K | 1.84M | 6.64% |
| 2024-09-29 | O'Connor, A Distinct Business Unit of UBS Asset Mgmt Americas (LLC) | 162.66K | 975.98K | 3.53% |
| 2024-09-29 | Millennium Management Llc | 140.73K | 844.39K | 3.05% |
| 2024-09-29 | Vanguard Group Inc | 53.57K | 321.42K | 1.16% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 26.44K | 158.65K | 0.57% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 26.30K | 157.78K | 0.57% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 20.83K | 124.95K | 0.45% |
| 2024-10-30 | Fidelity Total Market Index Fund | 8.35K | 50.11K | 0.18% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 5.00K | 29.98K | 0.11% |
| 2024-10-30 | Fidelity NASDAQ Composite Index Fund | 1.48K | 8.89K | 0.03% |
Split
| Split | Date |
|---|---|
| 1 : 50 | 2026-05-11 |
| 1 : 50 | 2022-10-21 |
| 2 : 1 | 2022-08-26 |